20/20 Biolabs receives second Nasdaq notice over stockholders' equity shortfall
20/20 Biolabs, Inc. (AIDX) received a Nasdaq notice on September 3, 2026 saying it does not meet the $2,500,000 stockholders' equity requirement, based on its Form 10-Q showing $1,620,700 at June 30, 2026. The company has 45 calendar days to submit a compliance plan, and failing to regain compliance could bar it from the extra time it would otherwise get on the bid price issue, adding delisting risk for shareholders.
Key points
- September 3, 2026: Nasdaq notice citing stockholders' equity of $1,620,700 versus a $2,500,000 requirement
- Company has 45 calendar days to submit a plan to regain compliance; Nasdaq may grant up to 180 more days if accepted
- Separate July 17, 2026 notice on the $1.00 bid price rule; compliance deadline is January 13, 2027
- Missing the equity rule by January 13, 2027 would disqualify the company from a second bid price compliance period
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.